检索结果 - Alona Zer

Refine Results
  1. 1
    Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis

    Hospitalisations and emergency department visits in cancer patients receiving systemic therapy: Systematic review and meta-analysis 由 Rebecca M. Prince, Melanie Powis, Alona Zer, Eshetu G. Atenafu, Monika K. Krzyzanowska

    出版 2018
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival

    Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival 由 Anna May Suidan, Laila C. Roisman, Anna Belilovski Rozenblum, Maya Ilouze, Elizabeth Dudnik, Alona Zer, Nir Peled

    出版 2019
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer

    A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer 由 Daniel A. Goldstein, Noa Gordon, Michal Davidescu, Moshe Leshno, Conor Steuer, Nikita Patel, Salomon M. Stemmer, Alona Zer

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

    Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer 由 Yosef Landman, Oded Jacobi, Noga Kurman, Orly Yariv, Idit Peretz, Ofer Rotem, Elizabeth Dudnik, Alona Zer, Aaron M. Allen

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data

    Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world da... 由 Elizabeth Dudnik, Mor Moskovitz, Yakir Rottenberg, Anastasiya Lobachov, Rinat Mandelboim, Tzippy Shochat, Damien Urban, Mira Wollner, Hovav Nechushtan, Ofer Rotem, Alona Zer, Sameh Daher, Jair Bar

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    Abdominal Desmoid: Course, Severe Outcomes, and Unique Genetic Background in a Large Local Series

    Abdominal Desmoid: Course, Severe Outcomes, and Unique Genetic Background in a Large Local Series 由 Ophir, Gilad, Sivan, Shamai, Hana, Strul, Guy, Rosner, Nathan, Gluck, Naomi, Fliss Isakov, Joseph, Klausner, Ido, Wolf, Ofer, Merimsky, Yael, Goldberg, Zohar, Levi, Alona, Zer, Revital, Kariv

    出版 2021
    获取全文 获取全文 获取全文
    Text
    加到收藏夹
    Saved in:
  7. 7
    Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung

    Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung 由 Elizabeth Dudnik, Samuel A. Kareff, Mor Moskovitz, Chul Kim, Stephen V. Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

    Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated with Epidermal Growth Factor... 由 Alona Zer, Keyue Ding, Siow Ming Lee, Glenwood Goss, Lesley Seymour, Peter Ellis, Allan Hackshaw, Penelope A. Bradbury, Lei Han, Christopher J. O’Callaghan, Ming‐Sound Tsao, Frances A. Shepherd

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer

    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer 由 Smadar Laufer‐Geva, Anna Belilovski Rozenblum, Tal Twito, R Grinberg, Addie Dvir, Lior Soussan‐Gutman, Maya Ilouze, Laila C. Roisman, Elizabeth Dudnik, Alona Zer, Ofer Rotem, Richard B. Lanman, Nir Peled

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Primary cardiac sarcomas: A multi‐national retrospective review

    Primary cardiac sarcomas: A multi‐national retrospective review 由 Tom Wei‐Wu Chen, Herbert H. Loong, Amirrtha Srikanthan, Alona Zer, Reeta Barua, Jagdish Butany, Robert J. Cusimano, Yun‐Chieh Liang, Chin‐Hao Chang, Zaza Iakobishvili, Albiruni R. Abdul Razak, Jeremy Lewin

    出版 2018
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors

    Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors 由 Oded Icht, Naama Darzi, Shai Shimony, Oded Jacobi, Daniel Reinhorn, Yosef Landman, Raz Mutai, Itamar Averbuch, Tzippy Shochat, Galia Spectre, Pia Raanani, Ofer Rotem, Elizabeth Dudnik, Nir Peled, Alona Zer, Avi Leader

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade

    Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade 由 Michal Harel, Coren Lahav, Eyal Jacob, Nili Dahan, Itamar Sela, Yehonatan Elon, Shani Raveh Shoval, Galit Yahalom, Iris Kamer, Alona Zer, Ofer Sharon, David P. Carbone, Adam P. Dicker, Jair Bar, Yuval Shaked

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

    Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer 由 Amir Massarweh, Noa Eliakim‐Raz, Amos Stemmer, Adva Levy‐Barda, Shlomit Yust‐Katz, Alona Zer, Alexandra Benouaich‐Amiel, Haim Ben‐Zvi, Neta Moskovits, Baruch Brenner, Jihad Bishara, Dafna Yahav, Boaz Tadmor, Tal Zaks, Salomon M. Stemmer

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

    BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors 由 Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Mira Wollner, Amir Onn, Abed Agbarya, Mor Moskovitz, S. Keren, Noa Popovits‐Hadari, Damien Urban, Moshe Mishaeli, Alona Zer, Aaron M. Allen, Natalie Maimon Rabinovich, Ofer Rotem, Teodor Kuznetsov, Tzippy Shochat, Laila C. Roisman, Jair Bar

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer

    Association of Neurocognitive Deficits With Radiotherapy or Chemoradiotherapy for Patients With Head and Neck Cancer 由 Alona Zer, Gregory R. Pond, Albiruni R. Abdul Razak, Kattleya Tirona, Hui Gan, Eric X. Chen, Brian O’Sullivan, John Waldron, David P. Goldstein, Ilan Weinreb, Andrew Hope, John J. Kim, Kelvin Chan, Andrew K. Chan, Lillian L. Siu, Lori J. Bernstein

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC

    IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as firs... 由 Federico Cappuzzo, Michael McCleod, Maen Hussein, Alessandro Morabito, Achim Rittmeyer, Henry Jacob Conter, Hans‐Georg Kopp, Davey B. Daniel, Steve McCune, Tarek Mekhail, Alona Zer, Niels Reinmuth, A. Sadiq, Venice Archer, Tania Ochi Lohmann, L. Wang, Marcin Kowanetz, Wei‐Hsin Lin, A. Sandler, Howard West

    出版 2018
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

    NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC 由 Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid, Konstantinos Syrigos, Claudio Martín, Nobuyuki Yamamoto, Ying Cheng, Vladimir Moiseyenko, Yvonne Summers, Ihor Vynnychenko, Sung Yong Lee, Maciej Bryl, Alona Zer, Mustafa Erman, Constanta Timcheva, Rajiv Raja, Kirsha Naicker, Urban Scheuring, Jill Walker, Helen Mann, Vikram K. Chand, Tony Mok

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

    Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies 由 Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín, Jan H.M. Schellens, Steven Kao, Wilson H. Miller, Jean‐Pierre Delord, Bo Gao, David Planchard, Maya Gottfried, Alona Zer, Shadia I. Jalal, Nicolas Penel, Janice M. Mehnert, Ignacio Matos, Jaafar Bennouna, Dong‐Wan Kim, Lei Xu, Suba Krishnan, Kevin Norwood, Patrick A. Ott

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN)

    UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) 由 Jair Bar, Nir Peled, Shiruyeh Schokrpur, Mirjana Wolner, Ofer Rotem, Nicolas Girard, Frank Aboubakar Nana, Sofie Derijcke, Waleed Kian, Sandip Pravin Patel, Hadas Gantz-Sorotsky, Alona Zer, Mor Moskovitz, Giulio Metro, Yakir Rottenberg, Antonio Calles, Maximilian J. Hochmair, Kristof Cuppens, Lynn Decoster, Martin Reck, Dror Limon, Estelamari Rodríguez, Christoforos Astaras, Adrienne Bettini, Simon Häfliger, Alfredo Addeo

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program

    Real-world experience with capmatinib in <i>MET</i> exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program 由 Oliver Illini, Hannah Fabikan, Aurélie Swalduz, Anders Vikström, Dagmar Krenbek, Michael A. Schumacher, Elizabeth Dudnik, Michael Studnicka, R. Öhman, Robert Wurm, Luciano Wannesson, Nir Peled, Waleed Kian, Jair Bar, Sameh Daher, Alfredo Addeo, Ofer Rotem, Georg Pall, Alona Zer, Akram Saad, Tanja Čufer, Hadas Sorotsky, Sayed M.S. Hashemi, Katja Mohorčič, Ronen Stoff, Yulia Rovitsky, Shoshana Keren-Rosenberg, Thomas Winder, Christoph Weinlinger, Arschang Valipour, Maximilian J. Hochmair

    出版 2022
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: